alirocumab vs ezetimibe
Side-by-side comparison of alirocumab and ezetimibe Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Zetia
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Ezetimibe and simvastatin is a combination medicine that helps lower cholesterol levels in your blood. It contains two drugs: ezetimibe and simvastatin.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
This medicine is used to lower high LDL cholesterol ('bad' cholesterol). It is used along with a healthy diet. It can help adults and children 10 years and older who have certain inherited high cholesterol conditions. Simvastatin, one of the drugs in this medicine, can also lower the risk of heart problems like heart attack and stroke in adults with heart or blood vessel disease.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Ezetimibe reduces the amount of cholesterol your body absorbs from food. Simvastatin belongs to a class of drugs called statins. Statins lower cholesterol by blocking a substance your body needs to make cholesterol.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Headache
- • Upper respiratory tract infection
- • Muscle pain
- • Diarrhea
- Muscle pain 1,655
- Missed dose 1,364
- Pain at injection site 1,278
- Muscle spasms 1,162
- Joint pain 1,053
- Tiredness 4,662
- Feeling sick to your stomach 4,195
- Muscle pain 4,191
- Diarrhea 3,661
- Medicine not working 3,517
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
This medicine can cause muscle problems, including rhabdomyolysis, which can lead to kidney damage and death. The risk is higher if you are over 65, have kidney problems, have thyroid problems, or take certain other medicines. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor may do blood tests to check your liver before and during treatment.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
Do not take ezetimibe and simvastatin if you are pregnant. It can harm your unborn baby. Talk to your doctor about other ways to lower your cholesterol if you are pregnant or planning to become pregnant. Breastfeeding is not recommended while taking this medicine.
Also Compare — Nearby Drugs
Compare alirocumab with
How to Read This alirocumab vs ezetimibe Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while ezetimibe sits within the Cholesterol Absorption Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while ezetimibe has 20,226. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between alirocumab and ezetimibe — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.